Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) and Distribution Solutions Group (NASDAQ:DSGR – Get Free Report) are both small-cap industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Valuation and Earnings
This table compares Cyclacel Pharmaceuticals and Distribution Solutions Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclacel Pharmaceuticals | $750,000.00 | 6.99 | -$3.00 million | ($4.54) | -0.21 |
| Distribution Solutions Group | $2.05 billion | 0.78 | $8.35 million | $0.19 | 183.58 |
Volatility and Risk
Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Distribution Solutions Group has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Insider and Institutional Ownership
23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.6% of Distribution Solutions Group shares are owned by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 78.8% of Distribution Solutions Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Cyclacel Pharmaceuticals and Distribution Solutions Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclacel Pharmaceuticals | N/A | -51.21% | -44.00% |
| Distribution Solutions Group | 0.44% | 9.33% | 3.41% |
Analyst Recommendations
This is a summary of recent recommendations for Cyclacel Pharmaceuticals and Distribution Solutions Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Distribution Solutions Group | 0 | 4 | 0 | 0 | 2.00 |
Distribution Solutions Group has a consensus price target of $35.00, indicating a potential upside of 0.34%. Given Distribution Solutions Group’s stronger consensus rating and higher possible upside, analysts plainly believe Distribution Solutions Group is more favorable than Cyclacel Pharmaceuticals.
Summary
Distribution Solutions Group beats Cyclacel Pharmaceuticals on 12 of the 13 factors compared between the two stocks.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
About Distribution Solutions Group
Distribution Solutions Group, Inc., a specialty distribution company, engages in the provision of value-added distribution solutions in North America, Europe, Asia, South America, and the Middle East. The company provides its solutions to the maintenance, repair, and operations (MRO); original equipment manufacturer (OEM); and industrial technology markets. It operates through three segments: Lawson, Gexpro Services, and TestEquity. The Lawson segment distributes of specialty products and services to the industrial, commercial, institutional, and government MRO market. The TestEquity segment distributes test and measurement equipment and solutions, industrial and electronic production supplies, and vendor managed inventory programs, as well as converting, fabrication, and adhesive solutions under the TestEquity, Hisco, TEquipment, Techni-Tool, Jensen Tools, and Instrumex brands. The Gexpro Services segment provides supply chain management solutions that offer VMI, kitting, global logistics management, manufacturing localization and import expertise, value engineering, and quality assurance. The company was formerly known as Lawson Products, Inc. and has changed to Distribution Solutions Group, Inc. 2022 Distribution Solutions Group, Inc. was incorporated in 1952 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
